In September 2026.
We have new arrivals Eloralintide 5mg.
Eloralintide (LY3841136) is a selective, long-acting amylin receptor (AMYR) agonist referenced in laboratory research examining amylin-pathway signalling, receptor-selectivity models, and next-generation selective amylin-agonist characterisation. A C-terminally amidated 37-amino-acid peptide featuring a Cys2–Cys7 methylene-thioacetal bridge and a Lys26 di-γ-glutamate / C20 diacid acyl side chain, it is documented in preclinical and Phase 1 proof-of-concept literature (Eli Lilly; ADA 2025 abstract 882-P; PMID 41109426) as a selective amylin-receptor agonist mechanistically distinct from nonselective amylin/calcitonin (e.g. cagrilintide) and dual incretin approaches. Supplied as a 10 mg lyophilized research material. For laboratory and research use only. Not for human or animal consumption. This product is not a therapeutic good, drug, supplement, food product, or cosmetic.
